Skip to main content
Clinical Trials/NCT01708733
NCT01708733CompletedPhase 2

An Evaluation of the Extract of KUAN SIN YIN on Hepatitis C: a Randomized, Double-blinded and Placebo-controlled Clinical Trial.

Taipei City Hospital1 site in 1 country57 target enrollmentStarted: August 2012Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
57
Locations
1
Primary Endpoint
HCV RNA titer

Study Overview

Brief Summary

The aim of the study is to examine whether the Chinese herbal formula (KSY) is effective on HCV Carrier With Abnormal Liver Function.

Detailed Description

percentage of change on HCV RNA titer and liver function (GPT).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Care Provider)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 40 < GPT <200 HCV carrier Age: 18-65 yrs old

Exclusion Criteria

  • Creatinine >2.0 mg/dL Total bilirubin > 2.0mg/dL Not suitable patients diagnosis by physician in charge.

Arms & Interventions

KSY

Experimental

KSY, 100mg decoction by mouth per day for 6 weeks

Intervention: KSY (Drug)

Outcomes

Primary Outcomes

HCV RNA titer

Time Frame: 6 weeks

Secondary Outcomes

  • Serum GPT level(6 weeks)

Investigators

Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Chung-Hua Hsu

chief medical officer

Taipei City Hospital

Study Sites (1)

Loading locations...

Similar Trials

The Effect of Chinese Herbal Formula (KSY)... | Clinical Trial